Q4 2025 Management View Jonathan DiVincenzo, President & COO, stated that Bio-Rad delivered results within revised guidance ...

Bio-Rad Laboratories BIO is something of a rarity: a small-cap company with a wide economic moat. The company develops products and solutions for the clinical diagnostics and life sciences industries, ...

Today, we will review the fourth quarter and full year 2025 financial results and provide an update on key business trends ...

In February 2026, Bio-Rad Laboratories reported fourth-quarter 2025 sales of US$693.2 million and net income of US$720 million, marking a return to profitability after a prior-year loss, alongside ...

If you are wondering whether Bio-Rad Laboratories is starting to look attractively priced after a rough few years, this ...

Bio-Rad Laboratories shares fell as the company faces margin pressure related to declining academic research funding. The stock slipped 10.6% to $261.43 Friday. Shares are down 14% over the past 12 ...

Bio-Rad Laboratories (BIO) has recently drawn investor attention after a period of weaker share performance, including a 12.3% decline over the past day and double digit negative returns over the past ...

In a report released on October 28, Brandon Couillard from Jefferies maintained a Buy rating on Bio-Rad Laboratories (BIO - Research Report), with a price target of $600.00. The companys shares closed ...

Bio-Rad Laboratories Inc. (BIO.B) on Thursday reported fourth-quarter net income of $720 million, after reporting a loss in the same period a ...

The earnings results for Bio-Rad Laboratories (NYSE: BIO) for Q4 were made public on Thursday, February 12, 2026 at 04:15 PM.

Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The growth stock trade ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 Earnings Call Transcript February 12, 2026 Bio-Rad Laboratories, Inc. misses on earnings expectations. Reported EPS is $2.51 EPS, expectations were $2.57.